Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3389562 | 0.86 | ALDH1A1 (0.61) | ALDH1A1ATMHTR2CHTR3EHTR3B | |
| SCHEMBL2908549 | 0.85 | HTR3E (0.52) | ALDH1A1HTR2CHTR3EHTR3BHTR3A | |
| SCHEMBL6773778 | 0.82 | PBRM1 (0.61) | HTR2CHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL31477966 | 0.82 | HTR2C (0.50) | ALDH1A1ATMHTR2CHTR3EHTR3B | |
| SCHEMBL15652258 | 0.82 | ALDH1A1 (0.61) | ALDH1A1ATMHTR2CPIM1PIM3 | |
| SCHEMBL1559466 | 0.81 | HTR3E (0.49) | ALDH1A1HTR2CHTR3EHTR3BHTR3A | |
| SCHEMBL8889647 | 0.81 | ALDH1A1 (0.59) | ALDH1A1ATMPIM1PIM3ADRA1A | |
| SCHEMBL16205922 | 0.81 | NR4A2 (0.67) | ALDH1A1ATMPIM1PIM3NR4A2 | |
| SCHEMBL26204498 | 0.81 | NR4A2 (0.65) | ALDH1A1ATMPIM1PIM3NR4A2 | |
| SCHEMBL1608195 | 0.79 | ALDH1A1 (0.57) | ALDH1A1ATMPIM1PIM3NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088768-B2 | Protein kinase and phosphatase inhibitors | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110136807-A1 | Bicyclic compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-7901894-B2 | Kinase inhibitors | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2011-03-08 | — | — | US | disclosed |
| US-20110028474-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2011-02-03 | — | — | US | disclosed |
| EP-1147214-B1 | A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS | UNIV NEW YORK STATE RES FOUND (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7838542-B2 | Bicyclic compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2010-11-23 | — | — | US | disclosed |
| US-7772216-B2 | Protein kinase and phosphatase inhibitors and methods for designing them | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2038254-A2 | BICYCLIC COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | Kinex Pharmaceuticals, LLC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7427608-B2 | Protection against and treatment of hearing loss | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2008-09-23 | — | — | US | disclosed |
| WO-2008002674-A2 | BICYCLIC COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2008-01-03 | — | — | WO | disclosed |
| US-7070936-B1 | Method for designing protein kinase inhibitors | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060089401-A1 | Kinase inhibitors | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2006-04-27 | — | — | US | disclosed |
| US-7005445-B2 | Protein kinase and phosphatase inhibitors and methods for designing them | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2006-02-28 | — | — | US | disclosed |
| US-20060030544-A1 | Protein kinase and phosphatase inhibitors and methods for designing them | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2006-02-09 | — | — | US | disclosed |
| EP-1444204-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS, METHODS FOR DESIGNING THEM, AND METHODS OF USING THEM | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040019015-A1 | Protection against and treatment of hearing loss | HEALTH RESEARCH, INC. (ROSWELL PARK DIVISION) | 2004-01-29 | — | — | US | disclosed |
| US-20030166615-A1 | Protein kinase and phosphatase inhibitors and methods for designing them | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2003-09-04 | — | — | US | disclosed |
| WO-2003035621-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS, METHODS FOR DESIGNING THEM, AND METHODS OF USING THEM | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2003-05-01 | — | — | WO | disclosed |
| EP-1147214-A1 | A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000042213-A1 | A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028474-A1 | PROTEIN KINASE AND PHOSPHATASE INHIBITORS | PTPN5, PTPN2, PTPN4 | ALDH1A1 4474/4885ATM 1136/4885HTR2C 3652/4885 |
| US-20060030544-A1 | Protein kinase and phosphatase inhibitors and methods for designing them | PTPN5, PTPN2, PTPN6 | ALDH1A1 4555/4885ATM 1060/4885HTR2C 3920/4885 |
| US-20040019015-A1 | Protection against and treatment of hearing loss | NTRK2, AIFM2, AIFM1 | ALDH1A1 2142/4885ATM 179/4885HTR2C 3381/4885 |
| US-20060089401-A1 | Kinase inhibitors | MAP3K5, MAP3K20, MAP4K5 | ALDH1A1 4824/4885ATM 677/4885HTR2C 4483/4885 |
| US-20110136807-A1 | Bicyclic compositions and methods for modulating a kinase cascade | MAP3K20, MAP3K6, MAP3K2 | ALDH1A1 4720/4885ATM 206/4885HTR2C 2662/4885 |
| US-20030166615-A1 | Protein kinase and phosphatase inhibitors and methods for designing them | PTPN5, PTPN2, PTPN6 | ALDH1A1 4555/4885ATM 1060/4885HTR2C 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.